For instance, HDAC inhibitor treatments in several cancer cell lines activate the ubiquitin–proteasome pathway, leading to increased protein degradation (Scognamiglio et al, 2008; Hakami et al, 2016; Kong et al, 2017). The gene discussed is HDAC9; the disease is cancer.